Camzyos Will Be a New Med for a Genetic Heart Condition

April 2023

You’ll hear about Camzyos (mavacamten), the first med approved for “obstructive hypertrophic cardiomyopathy”.

This genetic heart condition affects about 1 in 500 people.

These patients develop a thick and stiff heart muscle, which slows blood flow through the heart. This can lead to shortness of breath, chest pain, and fatigue.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Safety Stop Wrong-Patient Errors in Their Tracks
COVID-19 Continue to Identify Patients Who May Need a COVID-19 Booster
COVID-19 Help People Cope With Long COVID
Antibiotics Listen for Questions About Seizures With Cephalosporins
Menopause Be Familiar With Options to Manage Vaginal Menopausal Symptoms
Pain Management Expect More Buprenorphine Rxs for Chronic Pain
Med Safety Stay Alert for Tendon Problems With Aromatase Inhibitors
Cardiology Improve Safety With Heart Rhythm Meds
Cardiology Camzyos Will Be a New Med for a Genetic Heart Condition

Camzyos Will Be a New Med for a Genetic Heart Condition

Practical advice for a better career, with unlimited access to CE

Table of Contents